FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Laird Miers

Research Profile

Procedures

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Tumor Cells, Cultured

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Gerald L DeNardo; Arutselvan Natarajan; Saphon Hok; Julie Perkins; Monique Cosman; Sally J DeNardo; Felice C Lightstone; Gary R Mirick; Laird A Miers; Rod Balhorn
Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma.
Sally J DeNardo; Gerald L DeNardo; Arutselvan Natarajan; Laird A Miers; Allan R Foreman; Cordula Gruettner; Grete N Adamson; ROBERT IVKOV
Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice.
Laird A Miers; Sally J DeNardo; Kathleen R Lamborn; Gerald L DeNardo
Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Laird Miers (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2007: Gerald L DeNardo; Arutselvan Natarajan; Saphon Hok; Julie Perkins; Monique Cosman; Sally J DeNardo; Felice C Lightstone; Gary R Mirick; Laird A Miers; Rod Balhorn
Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007;48(8):1338-47.
2007: Sally J DeNardo; Gerald L DeNardo; Arutselvan Natarajan; Laird A Miers; Allan R Foreman; Cordula Gruettner; Grete N Adamson; ROBERT IVKOV
Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007;48(3):437-44.
2005: Laird A Miers; Sally J DeNardo; Kathleen R Lamborn; Gerald L DeNardo
Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft.
Cancer biotherapy & radiopharmaceuticals 2005;20(6):614-9.
2005: Laird A Miers; Kathleen R Lamborn; Aina Yuan; Carol M Richman; Arutselvan Natarajan; Sally J DeNardo; Gerald L DeNardo
Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 2):7158s-7163s.
2005: Sally J DeNardo; Gerald L DeNardo; Laird A Miers; Arutselvan Natarajan; Allan R Foreman; Cordula Gruettner; Grete N Adamson; ROBERT IVKOV
Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 2):7087s-7092s.
2003: Gerald L DeNardo; Sally J DeNardo; James J Peterson; Laird A Miers; Kit S Lam; Christine Hartmann Siantar; Kathleen R Lamborn
Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3865S-72S.
2003: Joseph M Tuscano; Robert T O'Donnell; Laird A Miers; Linda A Kroger; David L Kukis; Kathleen R Lamborn; Thomas F Tedder; Gerald L DeNardo
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
Blood 2003;101(9):3641-7.
2002: Patricia A Burke; Sally J DeNardo; Laird A Miers; Kathleen R Lamborn; Siegfried Matzku; Gerald L DeNardo
Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Cancer research 2002;62(15):4263-72.
2002: Patricia A Burke; Sally J DeNardo; Laird A Miers; David L Kukis; Gerald L DeNardo
Combined modality radioimmunotherapy. Promise and peril.
Cancer 2002;94(4 Suppl):1320-31.
2002: Robert T O'Donnell; Sally J DeNardo; Laird A Miers; Kathleen R Lamborn; David L Kukis; Gerald L DeNardo; Frederick J Meyers
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
The Prostate 2002;50(1):27-37.
2000: Robert T O'Donnell; Sally J DeNardo; Gerald L DeNardo; Laird A Miers; Kathleen R Lamborn; David L Kukis; Frederick J Meyers
Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
The Prostate 2000;44(3):187-92.
2000: Sally J DeNardo; Patricia A Burke; BR Leigh; Robert T O'Donnell; Laird A Miers; Linda A Kroger; Simon L Goodman; Siegfried Matzku; Alfred Jonczyk; Kathleen R Lamborn; Gerald L DeNardo
Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 2000;15(1):71-9.
1999: BR Leigh; Patricia A Burke; A M Hong; Robert T O'Donnell; Lydia Pleotis Howell; Laird A Miers; Gerald L DeNardo; Sally J DeNardo
Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 1999;14(2):113-9.
1998: Sally J DeNardo; Carol M Richman; David L Kukis; Sui Shen; Kathleen R Lamborn; Laird A Miers; Linda A Kroger; E A Perez; Gerald L DeNardo
Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
Anticancer research 1998;18(6A):4011-8.
1998: Robert T O'Donnell; Sally J DeNardo; Laird A Miers; David L Kukis; Gary R Mirick; Linda A Kroger; Gerald L DeNardo
Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
Cancer biotherapy & radiopharmaceuticals 1998;13(5):351-61.
1998: Gerald L DeNardo; Linda A Kroger; Claude F Meares; Carol M Richman; QA Salako; Sui Shen; Kathleen R Lamborn; James J Peterson; Laird A Miers; G R Zhong; Sally J DeNardo
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2483-90.
1998: Sally J DeNardo; David L Kukis; Laird A Miers; Michelle D Winthrop; Linda A Kroger; QA Salako; Sui Shen; Kathleen R Lamborn; Paul H Gumerlock; Claude F Meares; Gerald L DeNardo
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(5):842-9.
1997: Sally J DeNardo; Linda A Kroger; Kathleen R Lamborn; Laird A Miers; Robert T O'Donnell; David L Kukis; Carol M Richman; Gerald L DeNardo
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma.
Cancer 1997;80(12 Suppl):2583-90.
1997: Gerald L DeNardo; David L Kukis; Sally J DeNardo; Sui Shen; LF Mausner; Robert T O'Donnell; Kathleen R Lamborn; Frederick J Meyers; Suresh C Srivastava; Laird A Miers
Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2.
Cancer 1997;80(12 Suppl):2576-82.
1997: Sally J DeNardo; David L Kukis; Linda A Kroger; Robert T O'Donnell; Kathleen R Lamborn; Laird A Miers; DG DeNardo; Claude F Meares; Gerald L DeNardo
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(8):4000-4.
1997: Gerald L DeNardo; David L Kukis; Sui Shen; LF Mausner; Claude F Meares; Suresh C Srivastava; Laird A Miers; Sally J DeNardo
Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(1):71-9.
1995: Sally J DeNardo; Paul H Gumerlock; Michelle D Winthrop; Philip C Mack; S G Chi; Kathleen R Lamborn; Sui Shen; Laird A Miers; Ralph W deVere White; Gerald L DeNardo
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
Cancer research 1995;55(23 Suppl):5837s-5841s.
1995: M Li; Claude F Meares; QA Salako; David L Kukis; G R Zhong; Laird A Miers; Sally J DeNardo
Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
Cancer research 1995;55(23 Suppl):5726s-5728s.
1995: David L Kukis; Gerald L DeNardo; Sally J DeNardo; Gary R Mirick; Laird A Miers; D P Greiner; Claude F Meares
Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.
Cancer research 1995;55(4):878-84.
1994: M Li; Claude F Meares; G R Zhong; Laird A Miers; Cheng-Yi Xiong; Sally J DeNardo
Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.
Bioconjugate chemistry 1994;5(2):101-4.
1994: Gerald L DeNardo; Linda A Kroger; Sally J DeNardo; Laird A Miers; QA Salako; David L Kukis; I Fand; Sui Shen; Oliver Renn; Claude F Meares
Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).
Cancer 1994;73(3 Suppl):1012-22.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.